Literature DB >> 10619750

Intravenous cidofovir for compassionate use in AIDS patients with cytomegalovirus retinitis. Spanish Cidofovir Study Group.

J Berenguer1, J Mallolas.   

Abstract

We report the compassionate use of intravenous cidofovir for the treatment of cytomegalovirus retinitis in 51 patients with AIDS who were receiving highly active antiretroviral therapy (HAART). After a median of 9 doses, 49 patients showed no retinitis activity. However, treatment was stopped in 17 patients because of adverse reactions and in 5 patients for other reasons. Two deaths were considered related to the drug. Iritis developed in 21 patients (41.2%), a frequency higher than that reported during the pre-HAART era. Patients with iritis had median CD4 cell counts-both at nadir and at the initiation of cidofovir therapy-approximately 3 times higher than those for patients without iritis (P=.003 and P=.05, respectively). Our study confirms the efficacy of cidofovir therapy for AIDS-associated cytomegalovirus retinitis. Our data suggest that the risk of iritis may be higher for patients with better immunological status, probably because of their enhanced ability to mount an inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10619750     DOI: 10.1086/313593

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  4 in total

1.  Therapy and Prevention of Cytomegalovirus Retinitis.

Authors:  Asok Kurup; Francesca J. Torriani
Journal:  Curr Infect Dis Rep       Date:  2001-08       Impact factor: 3.725

2.  Correlation between cidofovir-associated uveitis and failing immunorestoration during HAART.

Authors:  E Tacconelli; M Tumbarello; R Rabagliati; G Scoppettuolo; A Minnella; G Ventura; R Cauda
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-02-15       Impact factor: 3.267

Review 3.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

Review 4.  Gastrointestinal cytomegalovirus disease in the immunocompromised patient.

Authors:  Allison L Baroco; Edward C Oldfield
Journal:  Curr Gastroenterol Rep       Date:  2008-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.